Evista
Authorised
This medicine is authorised for use in the European Union
raloxifene
MedicineHumanAuthorised
Overview
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).
Evista is a medicine containing the active substance raloxifene hydrochloride. It is available as white, oval tablets (60 mg).
Evista is used for the treatment and prevention of osteoporosis (a disease that makes bones fragile) in women who have been through the menopause. Evista has been shown to significantly reduce vertebral fractures (breaks in the spine), but not hip fractures.
The medicine can only be obtained with a prescription.
The recommended dose for adults and the elderly is one tablet taken once a day, with or without food. Patients may also receive calcium and vitamin D supplements if they do not get enough from their diet. Evista is intended for long-term use.
Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become thin and fragile, and more likely to break (fracture). Osteoporosis is more common in women after the menopause, when the levels of the female hormone oestrogen fall: oestrogen slows down bone breakdown and makes the bones less likely to fracture.
The active substance in Evista, raloxifene, is a selective oestrogen receptor modulator (SERM). Raloxifene acts as an ‘agonist’ of the oestrogen receptor (a substance that stimulates the receptor for oestrogen) in some tissues in the body. Raloxifene has the same effect as oestrogen in the bone, but it does not have an effect in the breast or the womb.
Evista has been studied in the treatment and the prevention of osteoporosis in four main studies.
Three studies looked at the prevention of osteoporosis in 1,764 women who took either Evista or placebo (a dummy treatment) for two years. The studies measured the density of the bones.
The fourth study compared the effects of Evista with those of placebo in the treatment of osteoporosis in 7,705 women over four years. The main measure of effectiveness was how many women had vertebral fractures during the study.
Evista was more effective than placebo in preventing and treating osteoporosis.
In the prevention of osteoporosis, women receiving Evista had an increase in bone density in the hip or spine of 1.6% over two years, and those receiving placebo had a decrease of 0.8%.
When used to treat osteoporosis, Evista was more effective than placebo in reducing the number of vertebral fractures. Over four years, in comparison with placebo, Evista decreased the number of new vertebral fractures by 46% in women who had osteoporosis and by 32% in women who had osteoporosis and an existing fracture. There was no effect of Evista on hip fractures.
The most common side effects with Evista (seen in more than 1 patient in 10) are vasodilation (hot flushes) and flu-like symptoms. For the full list of side effects reported with Evista, see the package leaflet.
Evista should not be used in women who:
- could become pregnant;
- have or have had any blood clot disorders, including deep vein thrombosis and pulmonary embolism (a blood clot in the lungs);
- have liver disease, severe kidney disease, unexplained bleeding from the womb or endometrial cancer (cancer of the lining of the womb).
Evista should not be used in people who may be hypersensitive (allergic) to raloxifene or any of the other ingredients.
The Committee for Medicinal Products for Human Use (CHMP) concluded that Evista had shown its effectiveness in preventing and treating osteoporosis, and had no effects on the breast or womb. The Committee decided that Evista’s benefits are greater than its risks for the treatment and prevention of osteoporosis in postmenopausal women. The Committee recommended that Evista be given marketing authorisation.
The European Commission granted a marketing authorisation valid throughout the European Union for Evista on 5 August 1998. The marketing authorisation was renewed on 5 August 2003 and on 5 August 2008. The marketing authorisation holder is Daiichi Sankyo Europe GmbH.
Product information
Latest procedure affecting product information: N/0090
02/06/2022
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- Evista
- Active substance
- raloxifene hydrochloride
- International non-proprietary name (INN) or common name
- raloxifene
- Therapeutic area (MeSH)
- Osteoporosis, Postmenopausal
- Anatomical therapeutic chemical (ATC) code
- G03XC01
Pharmacotherapeutic group
Sex hormones and modulators of the genital systemTherapeutic indication
Evista is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Evista or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.
Topics
This page was last updated on